|Bid||51.43 x 200|
|Ask||86.60 x 500|
|Day's Range||78.48 - 80.98|
|52 Week Range||38.43 - 83.84|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application (or NDA) for its investigational drug Elagolix, which is used for managing endometriosis-related pain, had been granted priority review by the FDA. AbbVie has developed Elagolix in collaboration with Neurocrine Biosciences (NBIX). AbbVie expects this oral gonadotropin-releasing hormone (or GnRH) antagonist to be approved by its Prescription Drug User Fee Act (or PDUFA) date in 2Q18.
After reading Neurocrine Biosciences Inc’s (NASDAQ:NBIX) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past andRead More...
Mid-caps stocks, like Neurocrine Biosciences Inc (NASDAQ:NBIX) with a market capitalization of $6.53B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
Neurocrine charged many patients twice the price of the drug in the latest quarter—but it is coming to an end.
On November 1, 2017, Neurocrine Biosciences, Inc. (NBIX) announced financial results for the third quarter of 2017 and provided a business update. The company reported $45.8 million in revenues from the sale of INGREZZA® for the treatment of tardive dyskinesia (TD), which was way ahead of even the most optimistic expectations. On October 5, 2017, the company announced that the FDA approved the 80 mg capsule of INGREZZA®.
The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. (NASDAQ: NBIX )'s third-quarter results . Given the buoyancy surrounding Ingrezza, ...
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
Neurocrine Biosciences, Juno Therapeutics and Exelixis topped expectations, though Clovis Oncology lagged.
On a per-share basis, the San Diego-based company said it had a loss of 13 cents. The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research ...
In the first half of 2017, Neurocine Biosciences (NBIX) generated revenues of $6.3 billion and reported expenses on the cost of product sales of $61.0 million.